Jeroen G. te Marvelde

Author

Erasmus MC

Also Known As

J G te Marvelde, J. G. te Marvelde, J.G. te Marvelde, Jeroen G. Te Marvelde, Jeroen G. te Marvelde

Publications

3.5K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Radboud University Nijmegen Radboud University Medical Center Amsterdam UMC Location Vrije Universiteit Amsterdam Erasmus University Rotterdam

About

Jeroen G. te Marvelde is an author at Erasmus MC specializing in pathology, health sciences, and cytometry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	7	7	524
2	Medicine	7	7	524
3	Immunology	2	2	57
4	Cell Biology	1	1	45
5	Classical Hematology	1	1	37

Jeroen G. te Marvelde

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia Prisca Theunissen, Ester Mejstříková, Łukasz Sędek, Blood	2016	401
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells Vincent H. J. van der Velden, Jeroen G. te Marvelde, Patricia G. Hoogeveen, Blood	2001	333
Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: Reference patterns for age‐related changes and disease‐induced shifts Ellen G. van Lochem, Vincent H. J. van der Velden, Henk Wind, Cytometry Part B Clinical Cytometry	2004	329
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group Theresia M. Westers, Robin Ireland, Wolfgang Kern, Leukemia Hematological MalignancyFlow CytometryMyelodysplastic SyndromesMedicineMixed-phenotype Acute Leukemia	2012	243
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes Arjan A. van de Loosdrecht, Canan Alhan, Marie C. Béné, Haematologica	2009	236
Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol Vincent H. J. van der Velden, A van der Sluijs-Geling, B Gibson, Leukemia Hematological MalignancyHealth SciencesPediatric HematologyMedicineMixed-phenotype Acute Leukemia	2010	144
CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping A.E. Bras, Válerie de Haas, Arthur van Stigt, Cytometry Part B Clinical Cytometry	2018	122
Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group Theresia M. Westers, Eline M.P. Cremers, Uta Oelschlaegel, Haematologica	2016	96
Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. K Groeneveld, Jeroen G. te Marvelde, M W van den Beemd, PubMed	1996	81
Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting N Feller, Vincent H. J. van der Velden, Rik A. Brooimans, Blood Cancer Journal	2013	73

Page 1